Bempedoic acid vs ezetimibe added to statin therapy: Cardiovascular outcomes in the real-world-The BEYOND-REAL Study - PubMed
3 hours ago
- #Real-World Evidence
- #Cardiovascular Risk
- #Statin Therapy
- The BEYOND-REAL Study compared cardiovascular outcomes of bempedoic acid vs ezetimibe added to moderate-intensity statin therapy.
- Bempedoic acid showed a significantly lower risk of composite cardiovascular events (16.7%) compared to ezetimibe (22.8%).
- Despite ezetimibe achieving greater LDL-C reduction, all individual cardiovascular endpoints favored bempedoic acid.
- The study included 6,706 patients (3,353 per cohort) after matching, using data from the TriNetX global federated health research network.
- Findings suggest bempedoic acid may offer greater ASCVD risk reduction than currently reflected in clinical guidelines.